AKBA
Akebia Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.68
+1.51%Year over year
Reported trailing growth
- Revenue
- +7.5%
- EBITDA
- —
- EBIT
- —
- EPS
- +35.9%
- Free cash flow
- +1677.2%
- Operating cash flow
- +1829.2%
Forward estimates
Based on analyst estimates
- Revenue
- -35.3%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -6.9%
- EBITDA
- +92.3%
- EBIT
- +146.6%
- Net income
- +92.3%
- EPS
- +93.7%
- Free cash flow
- +267.1%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026